ClinicalTrials.gg
RecruitingNCT01000259Updated May 5, 2017

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

An observational study in Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer and Stage IIIC Ovarian Cancer, sponsored by Gynecologic Oncology Group. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Gynecologic Oncology Group · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Enrollment
174
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group — 1 open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Gynecologic Oncology Group.

Planned enrollment
7th of 11
174 · median 247
Started
2004
with 3 others
Observational
12 of 75
1 open now
Registered
62nd of 75
by date

Among the 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2004, is one of 12 observational ones, and was the 62nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Ovarian Neoplasms by Gynecologic Oncology Group, or all of them as a file.
02

Study summary

This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.

Read the detailed description

PRIMARY OBJECTIVES:

I. To validate the ability of intratumoral tumor-infiltrating T lymphocytes (TILs) to predict progression-free survival (PFS) in patients with suboptimally debulked advanced stage III or IV ovarian epithelial cancer.

II. To validate the ability of intratumoral TILs to predict PFS in patients with optimally debulked disease.

SECONDARY OBJECTIVES:

I. To validate the ability of intratumoral TILs to predict overall survival of patients with suboptimally debulked disease.

II. To validate the ability of intratumoral TILs to predict overall survival of patients with optimally debulked disease.

OUTLINE:

Patients are stratified according to status of debulked disease (suboptimal vs optimal).

Previously collected tumor tissue samples are analyzed for tumor-infiltrating lymphocytes (TIL) via immunohistochemistry and double immunofluorescence assays using standard immunostaining.

03

Conditions studied

  • Stage IIIA Ovarian Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IV Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of stage III or IV ovarian epithelial cancer and enrolled on Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial (GOG-0114, GOG-132, GOG-0158, or GOG-0162)
  • Must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources:

    • Patients enrolled on GOG-0136 and a GOG front-line platinum/taxol chemotherapy trial(GOG-0114, GOG-0132, GOG-0158, and GOG-0162)
    • Patients who have had either optimal or suboptimal cytoreductive surgery
    • Patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected
  • Evaluable patients must have had measurable or nonmeasurable disease
  • Demographic and follow-up data available
05

Study design

Enrollment
174 participants (estimated)

Groups and cohorts

  • Ancillary-Correlative

    Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.

    Other: Laboratory Biomarker Analysis

Interventions

  • OtherLaboratory Biomarker Analysis

    Samples are analyzed in laboratory studies

06

What researchers measure

Primary outcomes

  1. Overall survival curves

    The Kaplan-Meier method will be used to estimate the survival curves, and the log-rank test will be used to test the difference between survival curves for TIL positive and negative patients. All of the tests will be two-sided and the significant levels will be set a 0.05.

    Time frame: Baseline

  2. Progression-free survival curves

    The Kaplan-Meier method will be used to estimate the survival curves, and the log-rank test will be used to test the difference between survival curves for TIL positive and negative patients. All of the tests will be two-sided and the significant levels will be set a 0.05.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Gynecologic Oncology Group
    Philadelphia, Pennsylvania 19103, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a primary completion of Jan 2100. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2009
First posted
Oct 23, 2009
Start
Sep 2004
Primary completionEst.
Jan 2100
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01000259
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Sep 2004
Primary completion
Jan 2100 (estimated)
Last update
May 5, 2017

Study contacts

George Coukos
principal investigator · Gynecologic Oncology Group
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion